# Upregulation of Alpha-1 Receptors Upon Septic Shock?

> **NCT01856517** · PHASE2,PHASE3 · TERMINATED · sponsor: **Direction Centrale du Service de Santé des Armées** · enrollment: 40 (estimated)

## Conditions studied

- Septic Shock

## Interventions

- **DRUG:** Clonidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01856517
- **Lead sponsor:** Direction Centrale du Service de Santé des Armées
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2013-08
- **Final completion:** 2014-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856517, "Upregulation of Alpha-1 Receptors Upon Septic Shock?". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01856517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*